The role of stathmin expression in the differential diagnosis,
prognosis, and potential treatment of ovarian sex cord-stromal
tumors

J 2024

The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors

SAFANDA, Adam, Michaela Kendall BARTU, Romana MICHALKOVA, Marian SVAJDLER, Tetiana SHATOKHINA et. al.

Basic information

Original name

The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors

Authors

SAFANDA, Adam, Michaela Kendall BARTU, Romana MICHALKOVA, Marian SVAJDLER, Tetiana SHATOKHINA, Jan LACO, Radoslav MATEJ, Gabor MEHES, Jana DROZENOVA, Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Zuzana SPURKOVA (203 Czech Republic), Jozef SKARDA (203 Czech Republic), Maria HACOVA (203 Czech Republic), Monika NALEZINSKA (203 Czech Republic), Pavel DUNDR (203 Czech Republic) and Kristyna NEMEJCOVA (203 Czech Republic)

Edition

Diagnostic Pathology, London, BMC, 2024, 1746-1596

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30109 Pathology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.600 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1186/s13000-024-01541-x

UT WoS

001303631500001

Keywords in English

Stathmin; Immunohistochemistry; Ovarian tumors; Sex cord-stromal tumors; Ovary

Abstract

V originále

Background Stathmin, a cytosolic microtubule-destabilizing phosphoprotein involved in the regulation of mitosis, is widely expressed in various malignancies and acts as an adverse prognostic factor. Our research analyzed its immunohistochemical expression on a large cohort of ovarian sex cord-stromal tumors, evaluating its potential utility in differential diagnosis, prognosis, and therapeutic application. Methods We examined 390 cases of ovarian sex cord-stromal tumors including 281 adult granulosa cell tumors (AGCT), 5 juvenile granulosa cell tumors (JGCT), 33 Sertoli-Leydig cell tumors (SLCT), 50 fibromas/thecomas (F/T), 11 Leydig cell tumors/steroid cell tumors (LCT/SterCT), 5 sex-cord stromal tumors NOS (SCST-NOS), 3 Sertoli cell tumors (SCT), and 2 sclerosing stromal tumors (ScST). Immunohistochemical analysis was performed using TMAs. Results Strong expression (> 50%) was observed in all cases of AGCT, JGCT, SLCT, SCST-NOS, SCT and 1 ScST. The other case of ScST exhibited mild expression (5-10%). The negative cases included exclusively F/T and LCT/SterCT, with F/T showing 24% of negative cases and LCT/SterCT comprising 64% of negative cases. Conclusion The results of our study indicate that stathmin is neither a prognostic marker nor suitable for the differential diagnosis of challenging cases of ovarian sex cord-stromal tumors. However, its predictive value may be theoretically significant, as a decrease in stathmin expression potentialy influences response to chemotherapy treatment.

Links

LM2023033, research and development project

Name: Síť českých biobank

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

SAFANDA, Adam, Michaela Kendall BARTU, Romana MICHALKOVA, Marian SVAJDLER, Tetiana SHATOKHINA, Jan LACO, Radoslav MATEJ, Gabor MEHES, Jana DROZENOVA, Jitka HAUSNEROVÁ, Zuzana SPURKOVA, Jozef SKARDA, Maria HACOVA, Monika NALEZINSKA, Pavel DUNDR and Kristyna NEMEJCOVA. The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors. Diagnostic Pathology. London: BMC, 2024, vol. 19, No 1, p. 1-9. ISSN 1746-1596. Available from: https://dx.doi.org/10.1186/s13000-024-01541-x.

@article{2436097,
   author = {Safanda, Adam and Bartu, Michaela Kendall and Michalkova, Romana and Svajdler, Marian and Shatokhina, Tetiana and Laco, Jan and Matej, Radoslav and Mehes, Gabor and Drozenova, Jana and Hausnerová, Jitka and Spurkova, Zuzana and Skarda, Jozef and Hacova, Maria and Nalezinska, Monika and Dundr, Pavel and Nemejcova, Kristyna},
   article_location = {London},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s13000-024-01541-x},
   keywords = {Stathmin; Immunohistochemistry; Ovarian tumors; Sex cord-stromal tumors; Ovary},
   language = {eng},
   issn = {1746-1596},
   journal = {Diagnostic Pathology},
   title = {The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors},
   url = {https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-024-01541-x},
   volume = {19},
   year = {2024}
}

TY  - JOUR
ID  - 2436097
AU  - Safanda, Adam - Bartu, Michaela Kendall - Michalkova, Romana - Svajdler, Marian - Shatokhina, Tetiana - Laco, Jan - Matej, Radoslav - Mehes, Gabor - Drozenova, Jana - Hausnerová, Jitka - Spurkova, Zuzana - Skarda, Jozef - Hacova, Maria - Nalezinska, Monika - Dundr, Pavel - Nemejcova, Kristyna
PY  - 2024
TI  - The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors
JF  - Diagnostic Pathology
VL  - 19
IS  - 1
SP  - 1-9
EP  - 1-9
PB  - BMC
SN  - 17461596
KW  - Stathmin
KW  - Immunohistochemistry
KW  - Ovarian tumors
KW  - Sex cord-stromal tumors
KW  - Ovary
UR  - https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-024-01541-x
N2  - Background Stathmin, a cytosolic microtubule-destabilizing phosphoprotein involved in the regulation of mitosis, is widely expressed in various malignancies and acts as an adverse prognostic factor. Our research analyzed its immunohistochemical expression on a large cohort of ovarian sex cord-stromal tumors, evaluating its potential utility in differential diagnosis, prognosis, and therapeutic application. Methods We examined 390 cases of ovarian sex cord-stromal tumors including 281 adult granulosa cell tumors (AGCT), 5 juvenile granulosa cell tumors (JGCT), 33 Sertoli-Leydig cell tumors (SLCT), 50 fibromas/thecomas (F/T), 11 Leydig cell tumors/steroid cell tumors (LCT/SterCT), 5 sex-cord stromal tumors NOS (SCST-NOS), 3 Sertoli cell tumors (SCT), and 2 sclerosing stromal tumors (ScST). Immunohistochemical analysis was performed using TMAs. Results Strong expression (> 50%) was observed in all cases of AGCT, JGCT, SLCT, SCST-NOS, SCT and 1 ScST. The other case of ScST exhibited mild expression (5-10%). The negative cases included exclusively F/T and LCT/SterCT, with F/T showing 24% of negative cases and LCT/SterCT comprising 64% of negative cases. Conclusion The results of our study indicate that stathmin is neither a prognostic marker nor suitable for the differential diagnosis of challenging cases of ovarian sex cord-stromal tumors. However, its predictive value may be theoretically significant, as a decrease in stathmin expression potentialy influences response to chemotherapy treatment.
ER  -

SAFANDA, Adam, Michaela Kendall BARTU, Romana MICHALKOVA, Marian SVAJDLER, Tetiana SHATOKHINA, Jan LACO, Radoslav MATEJ, Gabor MEHES, Jana DROZENOVA, Jitka HAUSNEROVÁ, Zuzana SPURKOVA, Jozef SKARDA, Maria HACOVA, Monika NALEZINSKA, Pavel DUNDR and Kristyna NEMEJCOVA. The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors. \textit{Diagnostic Pathology}. London: BMC, 2024, vol.~19, No~1, p.~1-9. ISSN~1746-1596. Available from: https://dx.doi.org/10.1186/s13000-024-01541-x.

Detailed Information on Publication Record